Cancer Care


Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - Buparlisib for Patients with PI3K-Activated Tumors
Principal Investigator (?)
Study Number
The purpose of this signal seeking study is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.